List of Seven Cheap Biotech Stocks Expected to Grow, Seeking Alpha Reports (CHTP, TLON, HGSI, VNDA, OREX, SNTA, VICL)

Seeking Alpha lists Biotech stocks that are currently very cheap, but are anticipating significant growth in the future.

Chelsea Therapeutics (NASDAQ: CHTP) is one to watch, Seeking Alpha explains, “Chelsea Therapeutics (CHTP) is trading around $4. CHTP is a biotechnology company, based in North Carolina. These shares have traded in a range between $1.94 to $8.20 in the last 52 weeks. The 50 day moving average is $4.29 and the 200 day moving average is $4.69. CHTP is estimated to lose about 86 cents per share in 2011.” The report adds that, “According to Yahoo Finance, CHTP has about $47.5 million in cash and basically no debt. The cash balance is equal to about 77 cents per share.”

Another possible contender for growth is Talon Therapeutics (OTC: TLON). “This stock has all the stars lining up for it now, and is very likely to produce explosive gains. This company received a large investment from Warburg Pincus several months ago. Warburg is a highly respected investment firm with expertise in life sciences and biotech companies”, details the article.

Human Genome Sciences (NASDAQ: HGSI) is losing now explains Seeking Alpha, “These shares have a 52 week range of $20.56 and $33.50. The 50 day moving average is $26.54 and the 200 day moving average is $26.27. Earnings estimates for HGSI are for a loss of $1.54 per share in 2011, and a loss of 64 cents for 2012.” However, HGSI shares are forecasted to experience huge revenue growth in both 2011 and 2012.

Vanda Pharmaceuticals (NASDAQ: VNDA) makes the list due to a new schizophrenia drug that is going to be released. Orexigen Therapeutics (NASDAQ: OREX) is next and shouldn't remain cheap for long. Due to the fact the dip in price stems from a slip up with the FDA, investors' confidence should return fairly soon.

Synta Pharmaceuticals (NASDAQ: SNTA) shares are expected to gain, “This company is working on HSP90 inhibitors, (Ganetespib) which has shown up to 100 times greater potency in killing cancer cells and an improved safety profile when compared to other treatments”, says Seeking Alpha.

Finally, Vical (NASDAQ: VICL) is expected to gain for benefiting cancer treatment as well, “Allovectin-7, which is a treatment for melanoma, could provide good news from the phase 3 trials”.

This article may include mentions of rumors, chatter, or unconfirmed information. Readers should beware that while unconfirmed information may be correlated with increased volatility in securities, price movements based on unofficial information may change quickly based on increased speculation, clarification, or release of official news.

Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.